N@N

DANVERS, Mass.--([ BUSINESS WIRE ])--[ Abiomed Inc ]. (NASDAQ: ABMD), a leading provider of [ breakthrough heart support technologies ], today announced the appointment of Susan Vissers Lisa, CFA, as Senior Director of Investor Relations and Corporate Development. Ms. Lisa brings more than 20 years of capital markets and healthcare experience, as well as an extensive background in medical technology, financial analysis, and sales and marketing management.

"With a unique background across financial markets, the medical technology sector, and healthcare investors, Susie is well positioned to help Abiomed continue to grow shareholder value as we execute our plan to recover hearts with cost-effective patient outcomes."

aWe are extremely pleased to have Susie Lisa on board during an exciting time of continued growth and opportunity for the Company,a said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. aWith a unique background across financial markets, the medical technology sector, and healthcare investors, Susie is well positioned to help Abiomed continue to grow shareholder value as we execute our plan to recover hearts with cost-effective patient outcomes.a

Prior to joining Abiomed, Ms. Lisa was a Managing Director at Bank of America Merrill Lynch. During her 12 year tenure, she was head of Americas Specialist Sales from 2009 to 2011, managing a team of 20+ dedicated sector sales specialists across all sectors of the S&P, while also providing dedicated healthcare sales coverage to major institutional investor clients. In her equity research sales role from 2001 to 2011, Ms. Lisa helped market Bank of America Merrill Lynchas healthcare equity research and capital markets transactions to some of the most sophisticated healthcare investors in the U.S. and Europe, also working closely with colleagues in trading, derivatives, capital markets, and investment banking to help best position healthcare corporations with investors and drive strong investment returns.

Prior to her sales role, Ms. Lisa spent four years as a medical technology research analyst, both at Merrill Lynch and Cowen & Co. She began her career at J.P. Morgan in a variety of roles, including healthcare investment banking, convertible sales/trading, and internal management consulting.

Ms. Lisa, a Chartered Financial Analyst, received a bacheloras degree in political science from Duke University and a masteras of business administration from New York Universityas Stern School of Business.

aI am thrilled to join the leadership team at Abiomed given the companyas compelling growth profile, exciting product portfolio, and emerging profitability,a said Ms. Lisa. aI look forward to enhancing our investor relations and corporate development efforts as we execute our plan to make the Impella platform the standard of care for patients requiring circulatory support.a

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: [ www.abiomed.com ].

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recent Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.